...Median PFS was 29.3 months (95%CI 14.605-43.995) in endocrine maintenance therapy group and 14.8 months (95%CI 7.445-22.155) in capecitabine maintenance therapy group. For HR+ and HER2-MBC, after 1 st-line salvage combined chemotherapy, ET maintenance has a better survival benefits than CT,especially for ET-sensitive and non-visceral involved cases.